BR112021005539A2 - tratamento de baixa intensidade de transtornos hematológicos - Google Patents

tratamento de baixa intensidade de transtornos hematológicos Download PDF

Info

Publication number
BR112021005539A2
BR112021005539A2 BR112021005539-8A BR112021005539A BR112021005539A2 BR 112021005539 A2 BR112021005539 A2 BR 112021005539A2 BR 112021005539 A BR112021005539 A BR 112021005539A BR 112021005539 A2 BR112021005539 A2 BR 112021005539A2
Authority
BR
Brazil
Prior art keywords
cpx
days
cytarabine
treatment
less
Prior art date
Application number
BR112021005539-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Ronald Cheung
Stefan Faderl
Qi Wang
Original Assignee
Celator Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals, Inc. filed Critical Celator Pharmaceuticals, Inc.
Publication of BR112021005539A2 publication Critical patent/BR112021005539A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021005539-8A 2018-09-25 2019-09-25 tratamento de baixa intensidade de transtornos hematológicos BR112021005539A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736393P 2018-09-25 2018-09-25
US62/736,393 2018-09-25
US201862772372P 2018-11-28 2018-11-28
US62/772,372 2018-11-28
PCT/US2019/052952 WO2020068979A1 (en) 2018-09-25 2019-09-25 Low-intensity treatment of hematological disorders

Publications (1)

Publication Number Publication Date
BR112021005539A2 true BR112021005539A2 (pt) 2021-06-29

Family

ID=69950910

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021005539-8A BR112021005539A2 (pt) 2018-09-25 2019-09-25 tratamento de baixa intensidade de transtornos hematológicos

Country Status (11)

Country Link
US (3) US20240252522A1 (https=)
EP (1) EP3856198A4 (https=)
JP (1) JP2022502498A (https=)
KR (1) KR20210065962A (https=)
CN (1) CN113164502A (https=)
AU (1) AU2019350759A1 (https=)
BR (1) BR112021005539A2 (https=)
CA (1) CA3114002A1 (https=)
IL (1) IL281729A (https=)
MX (1) MX2021003527A (https=)
WO (1) WO2020068979A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778260A (zh) * 2015-11-11 2018-11-09 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
EP3856198A4 (en) * 2018-09-25 2022-06-22 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
EP4333822A1 (en) 2021-05-03 2024-03-13 Lead Discovery Center GmbH Composition comprising an inhibitor of mitochondrial transcription

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2462376C (en) 2001-10-03 2010-12-14 Celator Technologies Inc. Liposome loading with metal ions
CA2467064C (en) 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability
WO2005102359A1 (en) 2004-04-22 2005-11-03 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
EP4046640A1 (en) * 2007-02-16 2022-08-24 Rotalec IP Holdings LLC Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders
EP3572071A1 (en) 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes
CN108778260A (zh) * 2015-11-11 2018-11-09 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
BR112019001570A2 (pt) * 2016-07-28 2019-07-09 Novartis Ag terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
WO2018101214A1 (ja) 2016-12-01 2018-06-07 Ｊｘｔｇエネルギー株式会社 全芳香族液晶ポリエステル樹脂
EP3856198A4 (en) * 2018-09-25 2022-06-22 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
US11980636B2 (en) * 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Also Published As

Publication number Publication date
US20210393665A1 (en) 2021-12-23
US20240252522A1 (en) 2024-08-01
EP3856198A1 (en) 2021-08-04
CN113164502A (zh) 2021-07-23
KR20210065962A (ko) 2021-06-04
EP3856198A4 (en) 2022-06-22
CA3114002A1 (en) 2020-04-02
US12370207B2 (en) 2025-07-29
JP2022502498A (ja) 2022-01-11
MX2021003527A (es) 2021-05-27
AU2019350759A1 (en) 2021-04-22
IL281729A (en) 2021-05-31
US20260014183A1 (en) 2026-01-15
WO2020068979A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
Lin et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial
US12370207B2 (en) Low-intensity treatment of hematological disorders
Belderbos et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)
Ryu et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901
Wise-Draper et al. Future directions and treatment strategies for head and neck squamous cell carcinomas
Liu et al. Homologous recombination enhances radioresistance in hypopharyngeal cancer cell line by targeting DNA damage response
Kemnade et al. Phase I/II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population
Park et al. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer
DeZern et al. Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Siewert et al. Esophageal cancer: clinical management
US20240252526A1 (en) Treatment of hematological disorders
Ocvirk Advances in the treatment of metastatic colorectal carcinoma
BR112020016073A2 (pt) Métodos e terapia de combinação para tratar câncer do trato biliar
Bauknecht et al. Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study
Park et al. A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer
Charalambakis et al. Feasibility of induction docetaxel, cisplatin, 5-fluorouracil, cetuximab (TPF-C) followed by concurrent cetuximab radiotherapy for locally advanced head and neck squamous cell carcinoma
Li et al. p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy?
Huang et al. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial
Vounckx et al. 694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors
Zhang et al. Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma
Patterson Investigating the Mechanisms of Benefit of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Ovarian Cancer
Melichar et al. Hepatic arterial infusion in liver tumors of unknown, uncertain or unusual primary: single-center experience
You et al. A Multicenter Randomized Controlled Phase 3 Trial of Locoregional Radiotherapy in Combination with Chemotherapy in de novo Metastatic Nasopharyngeal Carcinoma
Socinski et al. P-796 A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC)
Abo-Touk et al. Prospective study of adjuvant fixed-dose gemcitabine plus docetaxel for stage I-II uterine leiomyosarcoma

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]